We have located links that may give you full text access.
Comparison of resin modified glass ionomer cement and composite resin in class II primary molar restorations: a 2-year parallel randomised clinical trial.
European Archives of Paediatric Dentistry : Official Journal of the European Academy of Paediatric Dentistry 2018 December
AIM: To compare the 2-year success rates of a Resin Modified Glass Ionomer Cement (RMGIC) with a composite resin in class II primary molar restorations.
METHODS: Healthy, cooperative children aged 4-7.5 years with at least one carious primary molar requiring a class II restoration were included in this parallel randomised trial and allocated on a 1:1 basis to composite resin (Z250, 3M ESPE) or RMGIC (Vitremer, 3M ESPE). Restorations were assessed semiannually up to 2 years clinically and radiographically using modified United States Public Health Service criteria, with the primary outcome being all-cause failure. Data were analysed per protocol by binomial linear regression with Relative Risks (RR) and their 95% confidence intervals (CI).
RESULTS: 55 patients were randomly allocated to either group and 44 analysed at 2 years; with 49 teeth in the Z250 and 55 teeth in the Vitremer group. The all-cause failure rate for both materials was 3% after 1 year (4 and 2% for Z250 and Vitremer, respectively) and 16% after 2 years (16% for both Z250 and Vitremer). Overall, no difference between materials could be found at 2 years (RR = 1.4; 95% CI 0.8, 2.4; P = 0.30). However, Vitremer was associated with more favourable gingival health compared to composite (RR = 0.2; 95% CI 0.1, 0.9; P = 0.03), but also occlusal wear, which was observed exclusively for Vitremer.
CONCLUSION: No significant difference was found in the overall performance of the two materials, making them suitable for class II primary molar restorations, although RMGIC presented more pronounced occlusal wear of limited clinical importance after 2 years.
METHODS: Healthy, cooperative children aged 4-7.5 years with at least one carious primary molar requiring a class II restoration were included in this parallel randomised trial and allocated on a 1:1 basis to composite resin (Z250, 3M ESPE) or RMGIC (Vitremer, 3M ESPE). Restorations were assessed semiannually up to 2 years clinically and radiographically using modified United States Public Health Service criteria, with the primary outcome being all-cause failure. Data were analysed per protocol by binomial linear regression with Relative Risks (RR) and their 95% confidence intervals (CI).
RESULTS: 55 patients were randomly allocated to either group and 44 analysed at 2 years; with 49 teeth in the Z250 and 55 teeth in the Vitremer group. The all-cause failure rate for both materials was 3% after 1 year (4 and 2% for Z250 and Vitremer, respectively) and 16% after 2 years (16% for both Z250 and Vitremer). Overall, no difference between materials could be found at 2 years (RR = 1.4; 95% CI 0.8, 2.4; P = 0.30). However, Vitremer was associated with more favourable gingival health compared to composite (RR = 0.2; 95% CI 0.1, 0.9; P = 0.03), but also occlusal wear, which was observed exclusively for Vitremer.
CONCLUSION: No significant difference was found in the overall performance of the two materials, making them suitable for class II primary molar restorations, although RMGIC presented more pronounced occlusal wear of limited clinical importance after 2 years.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app